B-1722 Bosutinib Isomer 1, Free Base, >99%

Related Terms : [LC Labs XP/XR™ — X-ray Proven/X-ray Referenced Structure™]

  • Size
  • US $
  • £
  • ¥
  • 25 mg
  • 37
  • 32
  • 28
  • 4,100
  • Add to Cart Qty:
  • In stock
  • 50 mg
  • 55
  • 48
  • 42
  • 6,200
  • Add to Cart Qty:
  • In stock
  • 100 mg
  • 89
  • 78
  • 69
  • 10,000
  • Add to Cart Qty:
  • In stock
  • 200 mg
  • 164
  • 144
  • 127
  • 18,400
  • Add to Cart Qty:
  • In stock
  • 500 mg
  • 388
  • 341
  • 302
  • 43,400
  • Add to Cart Qty:
  • In stock
  • 1 g
  • 687
  • 604
  • 535
  • 76,900
  • Add to Cart Qty:
  • In stock
  • 2 g
  • 1,275
  • 1,122
  • 993
  • 142,700
  • Add to Cart Qty:
  • In stock

Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.

To receive a Quotation for catalog sizes of this product and/or any other products, please add them to your shopping cart and click on the “REQUEST A QUOTATION” box.
Click Here to Request a Quotation for Larger Quantities Click Here to see what Shipping and Handling Costs would be to Your Country
  • M.W. 530.45
  • C26H29Cl2N5O3
  • [1391063-17-4]

Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO at 33 mg/mL; soluble in ethanol at 10 mg/ml with warming; very poorly soluble in water; maximum solubility in plain water is etimated to be about 10-50 µM; buffers, serum, or other additives may increase or decrease the aqueous solubility. Disposal: A.

Certificate of Analysis

  • This compound, our Cat. No. B-1722, which we now sell under the name Bosutinib Isomer 1, is an incorrect isomer of bosutinib. X-ray, NMR and melting point data that our firm has obtained indicate that the following 17 vendors have erroneously sold this compound to one or more normal customers in the biochemical reagent marketplace, under the name "bosutinib" (please visit http://www.pkcpharma.com/TwoOrMoreBosutinibs.html for extensive additional information about this problem): AK Scientific B-Bridge International LC Laboratories (part of PKC Pharma) Santa Cruz Biotechnology Wuhan Sunrise Alfa Aesar Biorbyt Ltd. LKT Laboratories Selleck Chemicals Xingcheng Chempharm Axon Medchem Biovision Inc. Medchem Express Symansis NZ Ltd. Eton Bioscience Reliable ChemTech Synkinase An 18th vendor has also erroneously sold an incorrect isomer of bosutinib. Published information and private communications we have received from Prof. Stefan Knapp's laboratory indicate that an 18th vendor, "Company A", also provided an incorrect isomer of bosutinib to the biochemical research reagents marketplace, specifically to the Knapp laboratory and perhaps to other laboratories. The Knapp group used the material from Company A in an X-ray crystallography study proving that the compound from Company A was not the correct bosutinib isomer. This X-ray study clearly distinguishes Company A's product from correct bosutinib, but the data obtained apparently could not conclusively establish the structure of the incorrect compound. Contrary to an erroneous report in Chemical and Engineering News, Company A is not Calbiochem, the latter having issued a public statement on this topic http://www.millipore.com/antibodies/flx4/bosutinib_inhibitor_announcement. We have not yet received permission from the Knapp laboratory to release the name of Company A. NOTE: The erroneous compound that the 17 vendors listed above all sold is the compound described on this page, namely "Bosutinib Isomer 1", Cat. No. B-1722, for which we have unambiguously proven the structure by X-ray crystallography.
  • LC Labs XP/XR™ — X-ray Proven/X-ray Referenced Structure™. The chemical structure of our Bosutinib Isomer 1 has been unambiguously proven by single-crystal X-ray crytallography.
  • We now sell the correct bosutinib isomer under our Cat. No. B-1788, "Bosutinib, Free Base".
  • Unpublished kinase assay data obtained by our parent company, PKC Pharmaceuticals, Inc., indicate that bosutinib and this incorrect isomer have significantly different kinase inhibitory properties (manuscript in preparation).
353